Charles Schwab Investment Management Inc. Has $34.97 Million Stock Position in Supernus Pharmaceuticals, Inc. $SUPN

Charles Schwab Investment Management Inc. lowered its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 703,625 shares of the specialty pharmaceutical company’s stock after selling 28,864 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Supernus Pharmaceuticals were worth $34,970,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the stock. State Street Corp increased its position in shares of Supernus Pharmaceuticals by 1.4% in the 4th quarter. State Street Corp now owns 2,219,228 shares of the specialty pharmaceutical company’s stock valued at $110,296,000 after buying an additional 31,668 shares in the last quarter. Vontobel Holding Ltd. bought a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at $216,000. Wells Fargo & Company MN increased its position in shares of Supernus Pharmaceuticals by 46.2% in the 4th quarter. Wells Fargo & Company MN now owns 61,072 shares of the specialty pharmaceutical company’s stock valued at $3,035,000 after buying an additional 19,306 shares in the last quarter. Brooklyn Investment Group bought a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at $201,000. Finally, MetLife Investment Management LLC increased its position in shares of Supernus Pharmaceuticals by 842.4% in the 4th quarter. MetLife Investment Management LLC now owns 303,716 shares of the specialty pharmaceutical company’s stock valued at $15,095,000 after buying an additional 271,488 shares in the last quarter.

Analyst Ratings Changes

SUPN has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Friday, March 27th. Craig Hallum set a $65.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Finally, Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $62.17.

Supernus Pharmaceuticals Trading Down 3.5%

SUPN stock opened at $49.43 on Friday. The stock has a 50-day moving average price of $50.53 and a two-hundred day moving average price of $49.90. The stock has a market cap of $2.87 billion, a PE ratio of -96.92, a price-to-earnings-growth ratio of 1.07 and a beta of 0.57. Supernus Pharmaceuticals, Inc. has a 1 year low of $30.83 and a 1 year high of $59.68.

Insider Activity

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 35,000 shares of the stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $50.37, for a total transaction of $1,762,950.00. Following the completion of the transaction, the chief executive officer owned 958,100 shares in the company, valued at approximately $48,259,497. This represents a 3.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Georges Gemayel sold 10,000 shares of the stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $53.71, for a total value of $537,100.00. Following the transaction, the director owned 28,159 shares of the company’s stock, valued at approximately $1,512,419.89. This trade represents a 26.21% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 120,881 shares of company stock worth $6,139,356. 8.80% of the stock is currently owned by insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.